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Leaving Relativity Behind
Quantitative Clinical Perfusion Imaging*
Frank M. Bengel, MD
Hannover, Germany
Functional imaging of myocardial perfusion under stress
and rest conditions is a mainstay in the clinical workup of
coronary artery disease (CAD) (1). An array of noninvasive
modalities is available. Single-photon emission computed
tomography is most widely used, but positron emission
tomography (PET), echocardiography, magnetic resonance
imaging, and computed tomography are increasingly popu-
lar alternatives.
See page 740
Independent of the modality, clinical myocardial perfu-
sion studies are traditionally analyzed for the presence of
relative regional perfusion defects. Using visual image anal-
ysis or semiautomated algorithms, regional defects are
detected if the imaging signal in a myocardial segment is
significantly reduced compared with the “best perfused”
segment with the strongest signal in the same set of images
(2,3). Such a pattern is thought to reflect regional ischemia,
and thus the presence of flow-limiting disease in the
respective coronary artery territory. The diagnostic and
prognostic value of this approach has been well established.
As a consequence, noninvasive perfusion imaging today is
considered a gatekeeper for invasive CAD workup, and a
guide for risk-based therapeutic decision making (4,5).
But this traditional concept of regional perfusion analysis
is imperfect due to its relative nature. Defining the presence,
severity, and extent of perfusion defects intraindividually in
1 region compared with another region of the same heart
does not account for possible interindividual differences in
absolute myocardial blood flow. If absolute flow is impaired
globally, a comparison of the best and worst perfused
regions will underestimate the severity of flow-limiting
disease (Fig. 1C vs. 1A and 1B). This explains the lower
accuracy of standard myocardial perfusion imaging for the
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from Siemens Medical Solutions.detection of multivessel CAD compared with single-vessel
disease (6). Also, a relative perfusion deficit in 1 myocardial
region may be present despite good flow to the entire
myocardium (Fig. 1A vs. 1B). Such a situation is likely to be
associated with a better outcome than a relative regional
deficit of the same size and extent in the presence of overall
severely reduced flow.
Hence, information about absolute myocardial blood flow
and flow reserve is desirable. It may help to overcome
limitations of the existing concept of relative regional
ischemia and may provide incremental value. To date,
however, clinical myocardial perfusion imaging protocols do
not include algorithms for absolute quantification of myo-
cardial blood flow. This is explained by the technical
challenges associated with absolutely quantitative flow im-
aging: For high reproducibility, absolute flow quantification
requires tracers that provide a robust imaging signal. To be
valid and accurate, the tracer signal should be proportional
to flow over a wide range. There are also high demands on
imaging hardware and software. Dynamic imaging capabil-
ity is needed to detect changes of the tracer signal over time,
with high temporal resolution. Last, thoroughly validated,
robust, and reproducible software is needed to extract
quantitative information from the dynamically imaged
tracer kinetic signal.
Among all available modalities, PET is best suited for
this purpose because it fulfills these criteria sufficiently (7).
he tracers nitrogen-13 ammonia and oxygen-15 water
ave been successfully validated for flow quantification.
hey have been applied for decades as powerful research
ools. Detrimental effects of distinct risk factors and bene-
cial effects of novel preventive and therapeutic measures on
oronary flow reserve and microvascular function have been
dentified in selected study groups (8–11). More recently,
eports about clinical application for CAD workup are
ncreasing. Those reports show that flow quantification
rovides high accuracy for clinical CAD detection (12) and
hat it predicts adverse outcome in cardiomyopathies and in
AD (13–16). However, the need for a costly on-site
yclotron limits the use of 13N-ammonia and 15O-water to
a small number of high-end academic centers.
The present trend of a broader clinical penetration of
myocardial perfusion PET imaging is mostly owing to the
commercial availability of another perfusion tracer,
rubidium-82 (82Rb) (7). 82Rb is an ultrashort-lived radio-
sotope that is produced by a strontium/rubidium generator.
his generator can be used for rapid elution of repeated
racer doses, side by side with a PET scanner, without the
eed for an on-site cyclotron. The success of this agent has
ontributed to an increasing number of clinical studies that
onfirm the diagnostic accuracy (17,18) and prognostic
alue (19,20) of myocardial perfusion PET in the workup of
AD. Similar to single-photon emission computed tomog-
aphy imaging, however, relative regional perfusion analysis
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as been considered a more challenging agent for absolute
ow quantification compared with 13N-ammonia and 15O-
water. Nevertheless, several groups have recently validated
algorithms for flow quantification using this clinical agent
(21–23), but no articles about a broader clinical application
have been published so far.
The study by Ziadi et al. (24) in this issue of the Journal
is innovative and timely because it reports on an incremental
value of absolute flow quantification over relative regional
perfusion analysis when using 82Rb PET clinically in
uspected or known CAD. Using in-house–developed and
alidated methodology, the authors quantified global myo-
ardial flow reserve in a relatively large group of more than
00 subjects who were referred for the assessment of
yocardial ischemia. Only relative regional perfusion anal-
sis was used for clinical decision making. During follow-up
or a little more than 1 year, cardiac event rates were
ignificantly higher in subjects with reduced global flow
eserve compared with those with higher flow reserve. This
Figure 1 Simplified Side-by-Side Display of Absolute
Flow Reserve and Relative Regional Perfusion
Donut shapes represent myocardial short-axis slices. Left upper quadrant rep-
resents the defect area with reduced perfusion. Values in the center represent
global flow reserve. Three different scenarios, with decreasing global flow
reserve, are shown. (A, B) Identical reduction of relative perfusion in defect
area, down to 60% of a normal region. Absolute flow reserve, however, is mark-
edly inferior in B versus A. (C) Markedly reduced global flow reserve involving
the defect and remote area. Relative regional analysis underestimates defect
severity and falsely suggests less severe disease than shown in A and B.as observed in a subgroup of patients with abnormalelative regional perfusion, but also in a subgroup with
ormal regional perfusion. The results of the study by Ziadi
t al. (24) support the notion that quantitative global flow
eserve predicts cardiovascular events independent of rela-
ive regional perfusion defects and that it may improve risk
tratification in patients investigated for myocardial isch-
mia. The study is important, not only because it highlights
he quantitative nature of PET as a unique strength of the
ethod.
Studies like the one by Ziadi et al. (24) may result in a
aradigm change in noninvasive functional imaging, away
rom the well-established, but relative concept of comparing
yocardial regions within the same individual, toward a
ruly quantitative approach in which clinical decision mak-
ng is based on absolute measures of flow. The hope is that
uantitative flow will be an accurate means not only for
dentification of candidates for an intervention, but also for
uidance and monitoring of noninvasive therapy.
More steps, however, need to be taken before “relativity”
n perfusion imaging can be left behind. Some questions are
ot yet answered by Ziadi et al. (24). First, the authors
eport on global flow reserve. Regional analysis of absolute
ow was only included in an exploratory analysis with
imited power. Larger studies will be necessary to determine
hether absolute regional flow reserve is superior for selec-
ion of candidates for targeted revascularization. Regional
nalysis also represents a greater challenge for modeling
ecause image noise is expected to be larger for a smaller
arget area. Second, the study focuses on flow reserve as an
ntegrated marker of stress and rest flow. The relative value
f stress versus rest flow remains unclear. Theoretically, if
tress flow would provide predictive power equal to flow
eserve, the rest study may be eliminated. Third, although
he most likely explanation for the improved predictive value
f absolute flow reserve is a better detection of hemody-
amically relevant macroscopic multivessel coronary disease,
dditional effects of microvascular disease cannot be distin-
uished. It is well-known that microvascular disease, asso-
iated with endothelial dysfunction, limits myocardial flow
eserve (25). The relative contribution of microvascular and
acrovascular disease to global flow reserve remains obscure
n patients with coronary stenosis, and the dominance of
ne over the other may have different therapeutic implica-
ions (targeted vs. systemic therapy). Addition of low-dose
omputed tomography angiography to determine the degree
f macroscopic vessel atherosclerosis in hybrid PET–
omputed tomography sessions may help to overcome this
ssue (26). Finally, some technical issues should be consid-
red because the authors used in-house developed software,
tailored infusion system for 82Rb, and a 3-dimensional
acquisition protocol that was developed and validated in
their laboratory in extensive previous studies. Caution
should be exercised in other less experienced laboratories if
quantification is implemented, and robustness and validity
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marks a starting point for the clinical implementation of
absolute flow quantification in myocardial perfusion imag-
ing protocols. It will stimulate subsequent projects that will
provide more evidence. Those follow-up projects will also
need to focus prospectively on the impact of absolute flow
measurements on therapeutic benefit, not only for interven-
tional but also for conservative treatment strategies. As
shown by the work of this group and others, flow quanti-
fication in 82Rb PET is obtained without additional radia-
ion dose, without extended imaging time, and without
dded risk for the patient. Commercial software solutions
re expected to enter the market soon. Similar to electro-
ardiographic gating several years ago, it is foreseeable that
bsolute flow will enter the clinics and become a routine
eature of myocardial perfusion analysis in the future.
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